A comparison of valsartan and captopril in patients with essential hypertension in Indonesia

International Journal of Clinical Practice

Volumn 53, Issue 4, 1999, Pages 268-272

  Prabowo, Pramonohadi ^a,f   Arwanto, A ^b   Soemantri, D ^a   Sukandar, E ^d   Suprihadi, H ^d   Parsudi, I ^b   Sulaiman Markum, M ^c   Kabo, P ^e   Ratmoko, ^a   Prodjosudjadi, W ^c  

^a Dr Sutomo Hospital   (India)

^b Dr Kariadi Hospital   (India)

^c CIPTO MANGUNKUSUMO HOSPITAL   (Indonesia)

^d Hasan Sadikin Hospital   (Indonesia)

^e Grestelina Hospital   (Indonesia)

^f c/o Dr Djaja Nataatmadja ^*  (Indonesia)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT; CAPTOPRIL; VALSARTAN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; ESSENTIAL HYPERTENSION; FEMALE; HEADACHE; HUMAN; INDONESIA; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MYALGIA; OUTPATIENT CARE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SITTING; VOMITING;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; CAPTOPRIL; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; TETRAZOLES; TREATMENT OUTCOME; VALINE;

EID: 0032995166     PISSN: 13685031     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (30)

1. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure. Fifth report. Arch Intern Med 1993; 153: 154-176.
2. Sealey JE, Laragh JH. The renin-angiotensin-aldosterone system for normal regulation of blood pressure and sodium and potassium homeostasis. In: Brenner BM, Laragh JH, Eds. Hypertension. New York: Raven Press 1990: 1287-1319.
3. Waeber B, Nussberger J, Brunner HR. Angiotensin-converting enzyme inhibitors in hypertension. In: Laragh JH, Brenner BM, Eds. Hypertension: pathophysiology, diagnosis and management, 2nd edn. New York: Raven Press 1995: 2861-2872.
4. Verme-Gibboney C. Oral angiotensin converting enyzme inhibitors. Am J Health Syst Pharm 1997; 54: 2689-2703.
5. Schoenberger JA, Testa M, Ross AD et al. Efficacy, safety and quality of life assessment of captopril antihypertensive therapy in clinical practice. Arch Intern Med 1990; 150: 301-306.
6. Jenkins AC, Dreslinski GR, Tadros SS et al. Captopril in hypertension: seven years later. J Cardiovasc Pharmacol 1985; 7(suppl): S96-S101.
7. Bental T, Lishner M, Lalkin A et al. Comparison of enalapril to captopril by 24-hour ambulatory blood pressure monitoring. J Clin Pharmacol 1997; 37: 514-519.
8. Martell N, Gill B, Marin R et al. Trough to peak ratio of once-daily lisinopril and twice-daily captopril in patients with essential hypertension. J Hum Hypertens 1998; 12: 69-72.
9. Kang PM, Landau AJ, Eberhardt RT, Frishman WH. Angiotensin II receptor antagonists: a new approach to blockade of the renin-angiotensin system. Am Heart J 1994; 127: 1388-1401
10. Weber MA. Angiotensin II receptor antagonists in the treatment of hypertension. Cardiol Rev 1997; 5: 72-80.
11. Skidgel RA, Erdoes EG. The broad substrate specificity of human angiotensin I converting enzyme. Clin Exper Hypertens 1987; A9: 243.
12. Israili ZH, Hall WD. Cough and angioneurotic edema associated with angiotensin-converting enzyme inhibitor therapy. Ann Int Med 1992; 117: 234-242.
13. Elliott WJ. Higher incidence of discontinuation of angiotensin converting enzyme inhibitors due to cough in black subjects. Clin Pharmacol Ther 1996; 60: 582-588.
14. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13: S59-S62.
15. Semple PF, Herd GW. Cough and wheeze caused by inhibitors of angiotensin-converting enzyme. N Engl J Med 1986; 314: 61.
16. Webb D, Benjamin N, Collier J, Robinson B. Enalapril induced cough. Lancet 1986; ii: 1094.
17. Oparil S, Dyke S, Harris F et al. The efficacy and safety of valsartan compared with placebo in the treatment of patients with essential hypertension. Clin Ther 1996; 18: 797-810.
18. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
19. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-107.
20. Subcommittee of the WHO/ISH World Health Mild Hypertension Liaison Committee. Summary of the 1993 World Health Organisation-International Society of Hypertension guidelines for the management of mild hypertension. BMJ 1993; 307: 1541-1546.
21. Morice AH, Brown MJ, Higenbottam T. Cough associated with angiotensin converting enzyme inhibition. J Cardiovasc Pharmacol 1989; 13: S59-S62.
22. Lipsitz L, Orthostatic hypotension in the elderly. N Engl J Med 1989; 321: 952-957.
23. Corea L, Cardoni O, Fogari R et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: a comparative study of the efficacy and safety against amlodipine. Clin Pharmacol Ther 1996; 60: 341-346.
24. Benz J, Oshrain C, Henry D et al. Valsartan, a new angiotensin II receptor antagonist: a double-blind study comparing the incidence of cough with lisinopril and hydrochlorothiazide. J Clin Pharmacol 1997; 37: 101-107.
25. Black HR, Graff A, Shute D et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy, tolerability and safety compared to an angiotensin converting enzyme inhibitor, lisinopril. J Hum Hypertens 1997; 11: 483-489.
26. Mallion J-M, Boutelant S, Chabaux P et al. Valsartan, a new angiotensin II antagonist: blood pressure reduction in essential hypertension compared with an angiotensin converting enzyme inhibitor, enalapril. Blood Press Monit 1997; 2: 179-184.
27. Holwerda NJ, Fogari R, Angeli P et al. Valsartan, a new angiotensin II antagonist for the treatment of essential hypertension: efficacy and safety compared with placebo and enalapril. J Hypertens 1996; 14: 1147-1151.
28. Jamerson K, DeQuattro V. The impact of ethnicity on response to anti-hypertensive therapy. Am J Med 1996; 101: 22S-32S.
29. Lee EJ. Genetic polymorphisms in drug metabolism: its relevance to Asian populations. Am Acad Med Singapore 1991; 20: 56-60.
30. Mastana S, Nunn J. Angiotensin-converting enzyme deletion polymorphism is associated with hypertension in a Sikh population. Hum Hered 1997; 47: 250-253.